Talazoparib plus enzalutamide in men with metastatic castration-resistant prostate cancer: final overall survival results from the randomised, placebo-controlled, phase 3 TALAPRO-2 trial.
- DOI
- 10.1016/s0140-6736(25)00684-1
- Published
- 2025-07-16
- Container
- Lancet
- Publisher
- Not recorded
- Open access
- no
Credibility signals
limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1016/s0140-6736-25-00684-1,
title = {Talazoparib plus enzalutamide in men with metastatic castration-resistant prostate cancer: final overall survival results from the randomised, placebo-controlled, phase 3 TALAPRO-2 trial.},
author = {Agarwal N and Azad AA and Carles J and Fay AP and Matsubara N and Szczylik C and De Giorgi U and Young Joung J and Fong PCC and Voog E and Jones RJ and Shore ND and Saad F and Dunshee C and Zschäbitz S and Oldenburg J and Lin X and Healy CG and Kalac M and Kennedy D and Fizazi K.},
year = {2025},
journal = {Lancet},
doi = {10.1016/s0140-6736(25)00684-1},
url = {https://doi.org/10.1016/s0140-6736(25)00684-1}
}RIS
TY - JOUR TI - Talazoparib plus enzalutamide in men with metastatic castration-resistant prostate cancer: final overall survival results from the randomised, placebo-controlled, phase 3 TALAPRO-2 trial. AU - Agarwal N AU - Azad AA AU - Carles J AU - Fay AP AU - Matsubara N AU - Szczylik C AU - De Giorgi U AU - Young Joung J AU - Fong PCC AU - Voog E AU - Jones RJ AU - Shore ND AU - Saad F AU - Dunshee C AU - Zschäbitz S AU - Oldenburg J AU - Lin X AU - Healy CG AU - Kalac M AU - Kennedy D AU - Fizazi K. PY - 2025 JO - Lancet DO - 10.1016/s0140-6736(25)00684-1 UR - https://doi.org/10.1016/s0140-6736(25)00684-1 ER -
APA
N, A., AA, A., J, C., AP, F., N, M., C, S., U, D. G., J, Y. J., PCC, F., E, V., RJ, J., ND, S., F, S., C, D., S, Z., J, O., X, L., CG, H., M, K., D, K., & K., F. (2025). Talazoparib plus enzalutamide in men with metastatic castration-resistant prostate cancer: final overall survival results from the randomised, placebo-controlled, phase 3 TALAPRO-2 trial.. Lancet. https://doi.org/10.1016/s0140-6736(25)00684-1
Source records
- europe-pmc · retrieved 2026-09-26T13:53:58.348Z